128 related articles for article (PubMed ID: 38584352)
21. Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia.
Ko JH; Katako A; Aljuaid M; Goertzen AL; Borys A; Hobson DE; Kim SM; Lee CS;
Neurobiol Aging; 2017 Dec; 60():81-91. PubMed ID: 28934619
[TBL] [Abstract][Full Text] [Related]
22. Test-retest reproducibility of dopamine transporter density measured with [
Son HJ; Oh JS; Oh M; Lee SJ; Oh SJ; Chung SJ; Kim JS
Ann Nucl Med; 2021 Mar; 35(3):299-306. PubMed ID: 33387281
[TBL] [Abstract][Full Text] [Related]
23. Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson's disease.
Low A; Foo H; Yong TT; Tan LCS; Kandiah N
J Neurol Neurosurg Psychiatry; 2019 Jun; 90(6):681-687. PubMed ID: 30683708
[TBL] [Abstract][Full Text] [Related]
24. Comparison of perfusion 18F-FP-CIT PET and 99mTc-ECD SPECT in parkinsonian disorders.
Chun K; Kong E; Cho I
Medicine (Baltimore); 2021 Aug; 100(34):e27019. PubMed ID: 34449475
[TBL] [Abstract][Full Text] [Related]
25. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
[TBL] [Abstract][Full Text] [Related]
26. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
[TBL] [Abstract][Full Text] [Related]
27. In Vivo
Tang Y; Li L; Hu T; Jiao F; Han L; Li S; Xu Z; Fan Y; Sun Y; Liu F; Yen TC; Zuo C; Wang J
Mov Disord; 2023 Jan; 38(1):147-152. PubMed ID: 36368769
[TBL] [Abstract][Full Text] [Related]
28. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.
Bohnen NI; Koeppe RA; Minoshima S; Giordani B; Albin RL; Frey KA; Kuhl DE
J Nucl Med; 2011 Jun; 52(6):848-55. PubMed ID: 21571793
[TBL] [Abstract][Full Text] [Related]
29. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.
Colloby SJ; Firbank MJ; Pakrasi S; Lloyd JJ; Driver I; McKeith IG; Williams ED; O'Brien JT
Int Psychogeriatr; 2008 Dec; 20(6):1124-40. PubMed ID: 18752700
[TBL] [Abstract][Full Text] [Related]
30. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
Vander Borght T; Minoshima S; Giordani B; Foster NL; Frey KA; Berent S; Albin RL; Koeppe RA; Kuhl DE
J Nucl Med; 1997 May; 38(5):797-802. PubMed ID: 9170449
[TBL] [Abstract][Full Text] [Related]
31. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.
Hobson P; Meara J
Int J Geriatr Psychiatry; 2015 Oct; 30(10):1048-55. PubMed ID: 25676160
[TBL] [Abstract][Full Text] [Related]
32. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.
Eshuis SA; Jager PL; Maguire RP; Jonkman S; Dierckx RA; Leenders KL
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):454-62. PubMed ID: 19037637
[TBL] [Abstract][Full Text] [Related]
33. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
[TBL] [Abstract][Full Text] [Related]
34. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using
Cascianelli S; Tranfaglia C; Fravolini ML; Bianconi F; Minestrini M; Nuvoli S; Tambasco N; Dottorini ME; Palumbo B
Hell J Nucl Med; 2017; 20 Suppl():165. PubMed ID: 29324935
[TBL] [Abstract][Full Text] [Related]
35. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a
Pilotto A; Schiano di Cola F; Premi E; Grasso R; Turrone R; Gipponi S; Scalvini A; Cottini E; Paghera B; Garibotto V; Rizzetti MC; Bonanni L; Borroni B; Morbelli S; Nobili F; Guerra UP; Perani D; Padovani A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1642-1651. PubMed ID: 31098748
[TBL] [Abstract][Full Text] [Related]
36. "Parkinson-dementia" diseases: a comparison by double tracer SPECT studies.
Rossi C; Volterrani D; Nicoletti V; Manca G; Frosini D; Kiferle L; Unti E; De Feo P; Bonuccelli U; Ceravolo R
Parkinsonism Relat Disord; 2009 Dec; 15(10):762-6. PubMed ID: 19553153
[TBL] [Abstract][Full Text] [Related]
37. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
[TBL] [Abstract][Full Text] [Related]
38. Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study.
Jang H; Jang YK; Park S; Kim SE; Kim SJ; Cho SH; Youn J; Seo SW; Kim HJ; Na DL
Neurobiol Aging; 2020 Feb; 86():75-80. PubMed ID: 31843258
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease.
Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Suzuki K; Hasegawa T; Aoki M; Takeda A; Mori E
J Neurol Sci; 2017 Jan; 372():288-293. PubMed ID: 28017230
[TBL] [Abstract][Full Text] [Related]
40. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.
Edison P; Ahmed I; Fan Z; Hinz R; Gelosa G; Ray Chaudhuri K; Walker Z; Turkheimer FE; Brooks DJ
Neuropsychopharmacology; 2013 May; 38(6):938-49. PubMed ID: 23303049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
